Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer
about
Validation of functional imaging as a biomarker for radiation treatment responseImaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilitiesTowards multidimensional radiotherapy: key challenges for treatment individualisation.Positron emission tomography/computerized tomography in lung cancer.Prediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis.Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variabilityPredicting outcomes in radiation oncology--multifactorial decision support systemsMultiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation.Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy.Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study.Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy.Imaging and dosimetric errors in 4D PET/CT-guided radiotherapy from patient-specific respiratory patterns: a dynamic motion phantom end-to-end study.Quality assessment of positron emission tomography scans: recommendations for future multicentre trials.Present and future roles of FDG-PET/CT imaging in the management of lung cancer.Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot StudyFDG and Beyond.A radiobiological model of radiotherapy response and its correlation with prognostic imaging variables.Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review.Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.Impact of moving target on measurement accuracy in 3D and 4D PET imaging-a phantom study.The value of nodal information in predicting lung cancer relapse using 4DPET/4DCT.Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review.Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy.FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2)
P2860
Q26823165-B1AA2522-47EA-454B-8156-EABF96E69854Q27025204-E687323F-A1E2-4A92-B34D-ADA7AC596B17Q27687218-BAEE9A44-05F5-4EA0-85DA-C1CBCC002402Q33657999-753CC696-E526-4F26-A5B1-2B85EA33D45EQ34810709-83710B78-9204-4B6F-8131-05EAE23B01C4Q35916957-DD80FCD0-5BA3-4D23-AFD2-62716BF9DA63Q35945509-100FBFA7-2794-46E1-AF59-3F387C19D454Q36014711-D8DD71FD-B3B3-4101-B9BC-27839B8B4D11Q36427037-65248192-BF65-465B-AA65-8E96DF137CDDQ37227687-F12A66DB-8680-4665-A692-ED65C128C2BAQ37230607-4A790B4E-69BA-4063-8FF6-EE8A5DF371C5Q37273224-570AB68B-187C-466B-9467-CA101728FEB1Q37306472-2101AAA8-6159-4997-9680-87926ADFE66EQ37433626-CD2336C6-F19E-4D79-ACEB-E045A943AA48Q37601150-A9E99EAC-7BAC-4046-9C62-EABDC0A8FD49Q38169995-3AB8C2A4-3E69-4B20-B71A-9693CC01B7AEQ38401313-70927E09-2AF1-45C1-902B-6E9204A41D4BQ38401906-800E6349-05F6-4252-A2EC-FAEB6BF364ACQ38415240-8DBFCAF6-522D-4490-9BC4-67F7B83A6AFDQ38638684-CEEB8F4D-67BF-4D42-8977-F071C094880FQ38819166-B8A32C31-E154-46ED-9222-6EE18A2C0BA7Q38841400-986DC74B-C60E-4FE5-B947-0187FF52CF94Q38869438-AC40B74C-4F88-4F65-BFF6-D4636AD3EA92Q38989862-554BDE6B-236E-474D-BED2-55EF326EBBE2Q39417217-BD780813-4AD9-4D6F-A894-1E44C46370D4Q40872263-8F864B22-632A-4F7E-BEAB-C330A495AEEEQ40967181-BEDD7E35-CE9F-416C-8BC8-C98BBB1AC7F5Q41039688-0394417C-12AA-4EA5-9D09-EC0001F98F88Q45953810-C175AC42-5FA9-43C4-BFA1-EAC8FA5E6EEDQ47718840-81FAB423-65DB-4AAC-ACA6-9419B3C7ECA0Q47898194-9AB59C61-8D54-4CDC-AA76-0E0A02F81D40Q55398324-005CE3F7-D682-487E-A6B8-06C131333CF6Q56770246-9C607D68-EB3C-44D1-9BDE-FF628BE78307
P2860
Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Response assessment using 18F- ...... age non-small cell lung cancer
@ast
Response assessment using 18F- ...... age non-small cell lung cancer
@en
type
label
Response assessment using 18F- ...... age non-small cell lung cancer
@ast
Response assessment using 18F- ...... age non-small cell lung cancer
@en
prefLabel
Response assessment using 18F- ...... age non-small cell lung cancer
@ast
Response assessment using 18F- ...... age non-small cell lung cancer
@en
P2093
P2860
P1476
Response assessment using 18F- ...... age non-small cell lung cancer
@en
P2093
Anne-Marie C Dingemans
Michel Ollers
Philippe Lambin
P2860
P304
P356
10.2967/JNUMED.111.102566
P407
P577
2012-08-09T00:00:00Z